Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard Therapy

Phase I Study of the Fully Human Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody IMC-11F8 in Patients With Solid Tumors Who Have Failed Standard Therapy

The purpose of this study is to determine if IMC-11F8 is safe for patients, and also to determine the best dose of IMC-11F8 to give to patients.

Study Overview

• Status: Completed
• Conditions: Solid Tumors
• Intervention / Treatment: Biological: IMC-11F8; Biological: IMC-11F8; Biological: IMC-11F8; Biological: IMC-11F8 I.V.; Biological: IMC-11F8; Biological: IMC-11F8; Biological: IMC-11F8

Detailed Description

The purpose of this study is to establish the safety profile and the maximum tolerated dose (MTD) of the fully human anti-EGFR monoclonal antibody IMC-11F8 in patients with solid tumors who have filed standard therapy or for whom no standard therapy is available.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Amsterdam, Netherlands, 1081 HV
    • ImClone Investigational Site
  • Utrecht, Netherlands, 3508 GA
    • ImClone Investigational Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Histologically-confirmed, EGFR-detectable or EGFR-undetectable, unidimensionally-measurable and/or evaluable solid tumors who failed standard therapy or for whom no standard therapy is available. Patients who do not have tissue available for EGFR testing will undergo a biopsy of an accessible tumor.
• ECOG performance status score of ≤ 2 at study entry.
• Able to provide written informed consent.
• White blood cell (WBC) count ≥ 3 x 109/L; an absolute neutrophil count ≥ 1.5 x 109/L; a hemoglobin level > 90 g/L; and a platelet count ≥ 100 x 109/L.

• Adequate hepatic function as defined by:

  • an alkaline phosphatase level ≤ 5.0 x the ULN
  • a bilirubin level ≤ 1.5 x the ULN
  • aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x the ULN or ≤ 5 x the ULN for patients with liver metastases
• Adequate renal function as defined by a serum creatinine level within normal limits.
• Use of effective contraception if procreative potential exists.
• Life expectancy of approximately 3 months in the opinion the opinion of the investigator.

Exclusion Criteria:

• Chemotherapy, radiation, and/or hormonal therapy (except palliative radiation therapy for disease-related pain and chronic hormonal therapy for prostate carcinoma) within 4 weeks of study entry.
• Concurrent unstable or uncontrolled medical disease (e.g., active uncontrolled systemic infection, poorly controlled hypertension or history of poor compliance with an anti-hypertensive regimen, unstable angina, congestive heart failure, uncontrolled diabetes) or other chronic disease, which, in the opinion of the investigator, could compromise the patient or the study.
• Newly-diagnosed or symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids; anticonvulsants are allowed).
• Any concurrent malignancy other than basal cell carcinoma or carcinoma in situ of the cervix. Patients with a previous malignancy but without evidence of disease for ≥ 3 years will be allowed to enter the trial.
• Any condition that prevents the patient from providing informed consent.
• Pregnancy (confirmed by serum beta human chorionic gonadotropin [ßHCG]) or breast-feeding.
• Any investigational agent(s) or device(s) within 4 weeks of study entry.
• Prior treatment with cetuximab, or any other epidermal growth factor receptor inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib. Prior treatment with other monoclonal antibodies targeting receptors other than the EGFR is permitted ≥ 4 weeks prior to study entry.
• Any prior therapy that targeted the EGFR or EGFR pathway.
• Known history of human immunodeficiency virus.
• Employees of the investigator or study center with direct involvement in this study or other studies under the direction of the investigator or study center, as well as family members of the employees.

Study Plan

How is the study designed?

Design Details

• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: IMC-11F8 (Every week); Cycle of therapy administered intravenously, once a week for 6 weeks, for a total of six doses per cycle.	Biological: IMC-11F8; Cohort 1 100 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 2 200 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 3 400 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8 I.V.; Cohort 4 600 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 5 800 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 6 1000 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 4 600 mg I.V.; Other Names: necitumumab
EXPERIMENTAL: IMC-11F8 (Every other week); Cycle of therapy administered intravenously, every other week for 6 weeks, for a total of three doses per cycle.	Biological: IMC-11F8; Cohort 1 100 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 2 200 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 3 400 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 5 800 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 6 1000 mg I.V.; Other Names: necitumumab; Biological: IMC-11F8; Cohort 4 600 mg I.V.; Other Names: necitumumab

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of Participants with Adverse Events	Approximately 24 Months
Maximum Tolerated Dose of IMC-11F8	Approximately 24 Months

Secondary Outcome Measures

Outcome Measure	Time Frame
Area under the Time Concentration Curve (AUC)	Approximately 24 Months
Maximum concentration (Cmax)	Approximately 24 Months
Half-life (t 1/2)	Approximately 24 Months
Serum Anti-IMC-11F8 Antibody Assessment	Approximately 24 Months
Change from baseline in Antitumor Activity	Approximately 24 Months

Collaborators and Investigators

• Sponsor: Eli Lilly and Company

Publications and helpful links

General Publications

• Kuenen B, Witteveen E, Ruijter R, Ervin-Haynes A, Tjin-A-ton M, Fox F, et al. A phase I study of IMC-11F8, a fully human anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody in patients with solid tumors. Interim results. [abstract 3024 and poster presentation]. American Society of Clinical Oncology Annual Meeting. 2006 June 2-6; Atlanta, GA.
• Kuenen B, Witteveen PO, Ruijter R, Tjin-A-Ton M, Youssoufian H, Rowinsky E, et al. A phase I study of IMC-11F8, a recombinant human anti-epidermal growth factor receptor IgG1 monoclonal antibody in patients with solid tumors. [abstract B52 and poster presentaton] International Conference on Molecular Targets and Cancer Therapeutics 2007 Oct 22-26; San Francisco, CA.

Study record dates

Study Major Dates

• Study Start: November 1, 2004
• Primary Completion (ACTUAL): February 1, 2007
• Study Completion (ACTUAL): February 1, 2007

Study Registration Dates

• First Submitted: December 2, 2008
• First Submitted That Met QC Criteria: December 2, 2008
• First Posted (ESTIMATE): December 3, 2008

Study Record Updates

• Last Update Posted (ESTIMATE): October 13, 2010
• Last Update Submitted That Met QC Criteria: October 11, 2010
• Last Verified: October 1, 2010

More Information

Terms related to this study

• Keywords: Tumors; Antibodies, Monoclonal
• Additional Relevant MeSH Terms: Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Antibodies, Monoclonal; Necitumumab
• Other Study ID Numbers: 14088; 2004-002072-42 (EUDRACT_NUMBER); CP11-0401 (OTHER: ImClone, LLC)